Gainers

• Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million.
• Adagio Medical Holdings (NASDAQ:ADGM) stock moved upwards by 30.73% to $0.6. The market value of their outstanding shares is at $10.2 million.
• Galectin Therapeutics (NASDAQ:GALT) stock moved upwards by 20.46% to $3.65. The company's market cap stands at $199.5 million.
• Inspire Medical Systems (NYSE:INSP) stock moved upwards by 14.61% to $59.85. The company's market cap stands at $1.5 billion. The company's, Q2 earnings came out yesterday.
• Addex Therapeutics (NASDAQ:ADXN) stock increased by 12.49% to $5.85.
• Exagen (NASDAQ:XGN) shares rose 12.17% to $5.25. The company's market cap stands at $113.0 million. The company's, Q2 earnings came out today.

Losers

• AdaptHealth (NASDAQ:AHCO) shares decreased by 28.4% to $7.76 during Tuesday's pre-market session. The company's market cap stands at $1.4 billion. The company's, Q2 earnings came out today.
• Certara (NASDAQ:CERT) stock declined by 20.18% to $6.53. The company's market cap stands at $1.2 billion. The company's, Q2 earnings came out today.
• Prenetics Global (NASDAQ:PRE) shares decreased by 13.4% to $16.04. The market value of their outstanding shares is at $311.6 million.
• Pediatrix Medical Group (NYSE:MD) shares decreased by 12.39% to $23.0. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q2 earnings came out today.
• ClearPoint Neuro (NASDAQ:CLPT) stock decreased by 12.29% to $13.49. The company's market cap stands at $461.2 million. As per the news, the Q2 earnings report came out yesterday.
• Bruker (NASDAQ:BRKR) shares decreased by 12.15% to $56.5. The company's market cap stands at $9.7 billion. As per the press release, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.